In this pitch deck, analysts Melina Granberg, Tea Nedelkovska, and Julien Nguyen present an analysis of Medistim, a Norwegian MedTech firm specializing in devices for cardiovascular surgery. They highlight its resilient business model, strong competitive edge, and global commercialisation potential. Using valuation methods including DCF and LBO, they estimate a target valuation of NOK 3,299m – 4,505m. The following section outlines key assumptions underpinning the buyout case.
Key Takeaways
● Medistim’s razor–razorblade model ensures long-term customer lock-in and stable cash flows.
● As a leading provider in North America with limited competition, Medistim has pricing power to drive margins.
● Macroeconomic headwinds have led to an overreaction to APAC sales declines, depressing valuation and presenting an attractive opportunity
● Healthcare-focused private equity firms can drive global adoption by enforcing disciplined capital allocation and reinvesting into clinical studies